Ocugen, Inc.
(NASDAQ : OCGN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -1.14%349.580.0%$6651.77m
BNTXBioNTech SE 3.69%340.450.0%$1133.29m
SNSSSunesis Pharmaceuticals, Inc. 2.76%10.810.7%$755.66m
NVAXNovavax, Inc. 2.38%183.6079.8%$664.50m
AMGNAmgen, Inc. -0.19%241.081.3%$498.29m
BIIBBiogen, Inc. 2.08%333.521.7%$440.22m
VRTXVertex Pharmaceuticals, Inc. -1.16%199.251.9%$409.94m
GILDGilead Sciences, Inc. 0.29%68.491.0%$402.48m
REGNRegeneron Pharmaceuticals, Inc. 0.70%578.642.7%$356.37m
ILMNIllumina, Inc. 0.02%495.873.5%$264.07m
NTLAIntellia Therapeutics, Inc. -2.38%138.482.3%$257.63m
CRSPCRISPR Therapeutics AG 1.83%123.230.6%$147.37m
EXASEXACT Sciences Corp. 1.51%109.4718.1%$125.46m
SGENSeagen Inc. 0.84%154.685.8%$121.24m
XBIOXenetic Biosciences, Inc. 17.94%4.800.0%$120.51m

Company Profile

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.